Expression and clinical significance of the G1-S modulators in carcinoma of the extrahepatic bile duct

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 337-344

  Ito, Yasuhiro ^a,b   Takeda, Tsutomu ^a   Sakon, Masato ^c   Monden, Morito ^c   Tsujimoto, Masahiko ^d   Matsuura, Nariaki ^b,c  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d OSAKA POLICE HOSPITAL   (Japan)

Author keywords

Bile duct carcinoma; Cell cycle; G1 S modulators; Immunohistochemistry

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; BILE DUCT CARCINOMA; CANCER INVASION; CANCER STAGING; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; LABELING INDEX; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; BILE DUCT NEOPLASMS; CARCINOMA; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION; GENES, P16; GENES, P53; GENES, RETINOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; RETINOBLASTOMA PROTEIN; S PHASE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0034125594     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Sasaki K, Murakami T, Kawasaki M: The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 133: 579-584, 1987.
2. Suto T, Sugai T, Nakamura S, Funato O, Nitta H, Sasaki R, Kanno S, Saito K: Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. Cancer 82: 86-95, 1998.
3. Rijken AM, Umezawa A, van Gulik TM, Bosma A, Polak MM, Offerhaus GJ, Obertop H, Gouma DJ: Prognostic value of the cell proliferation (Ki-67 antigen) and nuclear DNA content in clinically resectable, distale bile duct carcinoma. Ann Surg Oncol 5: 699-705, 1998.
4. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryjia TP: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323: 643-646, 1986.
5. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevens JR The E2F transcription factor is a cellular target for the RB protein. Cell 65: 1053-1061, 1991.
6. Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E: The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J 10: 4279-4290, 1991.
7. Mittnacht Sj Lees JA, Desai D, Harlow E, Morgan DO, Weinberg RA Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J 13: 118-127, 1994.
8. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenbereg HM, Arnold A: A novel cyclin encoded by a bc11-linked candidate oncogene. Nature 350: 512-515, 1991.
9. Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF, Sherr CJ: Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71: 323-334, 1992.
10. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 705-707, 1993.
11. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D, p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993.
12. Poylak K, Lee M, Erdjument-Bromage A, Koff A, Roberts JM, Tempst P, Massague J: Cloning of p27KIP1, a cyclin -dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66, 1994.
13. Mori T, Miura K, Aoki T, Nishihara T, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54: 3396-3397, 1994.
14. Caldas C, Hahn SA, da Costa LT, Redston MS, Shibata A, Simoneau AR, Lin MF et al: p16 mutation in uncultured tumours. Nature 370: 183-184, 1994.
15. Kees UR, Ranford PR, Hatzis M: Deletions of the p16 gene in pediatric leukemia and corresponding cell lines. Oncogene 12: 2235-2239, 1996.
16. Zhou X, Tarmin L, Yin J, Jiang HY, Suzuki H, Rhyu MG, Abraham JM: The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9: 3737-3741, 1994.
17. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 371: 534-537, 1994.
18. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenopol JA et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Rest 54: 1169-1174, 1994.
19. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL et al: Absence of WAF1 mutations in a variety of human malignancies. Blood 84: 3781-3784, 1994.
20. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ: Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27KiP1) of cyclin -dependent kinase 4 activity. Cell 79: 487-496, 1994.
21. Nourse J, Firpo E, Flanagan MW, Coats S, Polyak K, Lee M, Massague J et al: Interleukin-2-mediated elimination of the p27KiP1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570-573, 1994.
22. Harvat LB, Seth P, Jatten AM: The role of p27KiP1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene 372: 570-573, 1997.
23. Kuniyasu X Yasui W, Kitahara K, Naka K, Yokozaki H, Akama Y, Hamamoto T et al: Growth inhibitory effect of interferon-beta is associated with the induction of cyclin dependent kinase inhibitor p27KiP1 in a human gastric cell line. Cell Growth Differ 8: 47-52, 1997.
24. General Rules for Surgery and Pathological Studies on Cancer of Biliary Tract. Japanese Society of Biliary Surgery. 3rd Edition, 1993.
25. Hermanek P, Sobin L, editors. UICC. TNM classification of malignant tumors (4th rev. ed.) Berlin, Springer-Verlag, 1992.
26. Zhang Y-J, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, Weinstein IB: Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophy Res Commun 196: 1010-1016, 1993.
27. Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, Amenomori M et al: Amplification and overexpression of the cyclin D1 gene in aggresssive human hepatocellular carcinoma. Cancer Res 54: 3107-3110, 1994.
28. Akervall JA, Michalides RJ, Mineta H, Balm A, Borg A, Dictor MR, Jin Y, Loftus B, Mertens F, Wennerberg JP: Amplification of cyclin D1 in squamous cell carclnoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 79: 380-389, 1997.
29. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995.
30. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta G, Jessup JM et al: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3: 231-234, 1997.
31. Porter PL, Malone KE, Heagerty P, Alexander GM, Gatti LA, Firpo EJ, Daling JR et al: Expression of cell-cycle regulators p27KiP1 and cycllin e, alone and in combination, corrrelate with survival in young breast cancer patients. Nat Med 3: 222-225, 1997.
32. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P et al: Decreased levels of the cell-cycle inhibitor p27KiP1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227-230, 1997.
33. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P et al: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57: 1259-1263, 1997.
34. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M et al: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381-3385, 1997.
35. Baas IO, Mulder J-WR, Johan G, Offerhaus A, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172: 5-12, 1994.
36. Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A: p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correrlation with tumor grade and survival. Hepatology 22: 774-779, 1995.
37. INK4B/MTS2 genes in billary tract cancers. Cancer Res 55: 2756-2760, 1995.
38. Wakasugi E, Kobayashi T, Tamaki Y, Ito Y, Miyashiro I, Komoike Y, Takeda T, Shin E, Takatsuka Y, Kikkawa N, Monden T, Monden M: p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol 107: 684-691, 1997.
39. Yasui W, Akama Y, Yokozaki H, Semba S, Kudo Y, Shimamoto F, Tahara E: Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression. Pathol Int 47: 470-477, 1997.